by Romain Magnez | Nov 10, 2024 | Publications
Human T-cell activation with Toxoplasma gondii antigens loaded in maltodextrin nanoparticles Vaxinano is pleased to present its latest publication, “Human T-cell activation with Toxoplasma gondii antigens loaded in maltodextrin nanoparticles”, published in Frontiers...
by Romain Magnez | Oct 29, 2024 | News
Vaxinano, sept 25th 2024, Lille- France : Vaxinano Secures €6 Million in Funding to Advance Nasal Vaccines to Clinical Trials Vaxinano, a pioneering biotech company specializing in the development of prophylactic and therapeutic nasal vaccines, has successfully raised...
by Romain Magnez | Oct 10, 2024 | News
Title: Pioneering Vaccine Solutions with Vaxinano’s STELLAR-NP Platform Description:Vaxinano is transforming vaccine development through our innovative STELLAR-NP technology, a groundbreaking nanoparticle-based platform that optimizes the delivery and efficacy of...
by Romain Magnez | Jul 30, 2024 | News
Vaxinano’s vaccine is presented in the Pairi Daiza Zoo collaboration For several years, we have been working together with Pairi Daiza to vaccinate monkeys against toxoplasmosis. We are delighted to share an episode of “Expedition Pairi Daiza”...
by Romain Magnez | Jul 30, 2024 | News
Our ONE Health mission is to protect all animals and all humans around the world. And we are grateful to count on Phileo by Lesaffre to support our vaccination strategy to endanger species. 📢 Today is the international hashtag#BiodiversityDay! A beautiful reminder of...
